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OBJECTIVES We sought to compare the long-term survival rates of patients with sustained ventricular
tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of
electrophysiological (EP) study either with amiodarone or an implantable cardioverter-
defibrillator (ICD).
BACKGROUND Patients with sustained ventricular tachyarrhythmias after MI are at high risk of sudden
cardiac death (SCD). However, data comparing the long-term survival rates of patients
treated with amiodarone or ICD, according to the results of EP testing, are lacking.
METHODS Patients underwent a first EP study at baseline and a second one after a loading dose of
amiodarone of 14  2.9 g. According to the results of the second EP study, patients were
classified either as responders or non-responders to amiodarone; non-responders were
eventually treated with an ICD.
RESULTS Eighty-four consecutive patients with MI (78 men; 21–77 years old; mean left ventricular
(LV) ejection fraction 36  11%) were consecutively included. Forty-three patients (51%)
were responders, and 41 patients (49%) were non-responders to amiodarone therapy. During
a mean follow-up period of 63 30 months, SCD and total mortality rates were significantly
higher in the amiodarone-treated patients (p  0.03 and 0.02, respectively).
CONCLUSIONS The long-term survival of patients with sustained ventricular tachyarrhythmias after MI, with
depressed LV function, is significantly better with an ICD than with amiodarone therapy,
even when stratified according to the results of the EP study. These patients should benefit
from early ICD placement, and any previous amiodarone treatment seems to have no
additional value. (J Am Coll Cardiol 2002;39:1813–9) © 2002 by the American College of
Cardiology Foundation
Until recently, electrophysiologically (EP) guided antiar-
rhythmic drug therapy was considered as the best conser-
vative approach for the management ventricular tachycardia
(VT) in patients at high risk of sudden cardiac death (SCD)
(1,2). After the results of the Cardiac Arrhythmia Suppres-
sion Trial (CAST), class III drugs, particularly amiodarone,
have been advocated as the best anti-arrhythmic drugs
available to treat these patients (3–6). However, amioda-
rone is usually prescribed empirically because the usefulness
of EP testing in predicting its efficacy remains controversial
(2,7–13).
Very recently, several trials have demonstrated that the
implantable cardioverter-defibrillator (ICD) is superior to
anti-arrhythmic drug treatment for the secondary preven-
tion of SCD (14–17); however, these trials suffer from an
imbalance in the use of beta-blockers, which could have
favored the beneficial effect of ICD (16,18). Furthermore, in
some of them, the cost per life-years saved was very high;
thus, careful patient selection before ICD implantation is
justified (18). Interestingly, the Canadian Implantable De-
fibrillator Study (CIDS) investigators have shown, in a
subgroup analysis, that patients at the highest risk of death,
identified on the basis of age, poor ventricular function and
poor functional status, benefited the most from ICD ther-
apy, whereas the lower-risk patients had little, if any, benefit
(19,20).
We are unaware of a study that compared EP-guided
amiodarone therapy with ICD therapy in terms of survival
in patients with sustained ventricular tachyarrhythmias. The
present study was thus performed prospectively to evaluate
the long-term outcomes in patients with sustained ventric-
ular tachyarrhythmia after myocardial infarction (MI)
treated with either amiodarone or ICD therapy, according
to the results of the EP study.
METHODS
Patients and treatment. Patients were recruited at our
institution between January 1987 and December 1995.
Patients between 20 and 80 years old who had an MI and a
first episode of documented, sustained VT or ventricular
fibrillation (VF) and inducible, sustained ventricular tachy-
arrhythmia during ventricular stimulation were consecu-
tively enrolled in the study. The study protocol was in
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agreement with the guidelines of the Ethics Committee of
our institution and was explained to all patients; oral
consent was obtained from each patient.
The study group consisted of 84 consecutive patients (78
men [93%] and 6 women [7%]; mean age 60  10 years).
All patients had a previous MI, and eight of them had their
arrhythmic event within two to four weeks after the MI.
The clinical presentation was syncope in 24 patients (29%),
palpitations in 23 patients (27%), dizziness in 17 patients
(20%), angina pectoris in nine patients (11%), aborted SCD
in nine patients (11%) and dyspnea in two patients (2%).
The mean left ventricular ejection fraction (LVEF) was
36  11%. The clinical documented arrhythmia was VT in
73 patients and VF in 11 patients.
All patients underwent programmed ventricular stimula-
tion while not receiving anti-arrhythmic drugs. A total of 81
patients had a baseline EP study: three patients (4%) could
not be studied in the basal state, as anti-arrhythmic drug
withdrawal was considered unsuitable because of spontane-
ous VT recurrence. In these three patients, the cycle length
of the documented clinical VT was used as the index
arrhythmia, to be compared with the cycle length of induced
VT treated with amiodarone.
After a mean loading dose of amiodarone of 1.2 g/day
during 8 to 15 days, all 84 patients underwent a second EP
study. According to the result of this second programmed
ventricular stimulation, patients were classified as “respond-
ers” or “non-responders” to amiodarone therapy.
The ventricular pacing protocol that we applied is de-
scribed elsewhere (21). Briefly, three pacing cycle lengths
with up to three extrastimuli at two stimulation sites at twice
the diastolic threshold in the right ventricle were used. The
end points of the pacing protocol were sustained, mono-
morphic VT, VF or completion of the protocol.
Definitions. Patients were considered as “amiodarone pre-
dicted responders” (group 1) after the second EP study if,
compared with baseline, VT was: 1) non-inducible; 2)
slowed to a mean cycle length 400 ms and was hemody-
namically well tolerated; or 3) slowed by15 beats/min and
was hemodynamically well tolerated. “Amiodarone pre-
dicted non-responders” (group 2) were inducible patients
with: 1) VF; 2) a VT cycle length 400 ms; 3) VT slowed
by 15 beats/min; or 4) any hemodynamically non-
tolerated VT. The induced ventricular arrhythmia was
considered as tolerated if it did not cause cardiovascular
collapse, angina, near syncope, dizziness or confusion or
systolic pressure 90 mm Hg after 5 min in the supine
position.
According to the results of the second EP study, respond-
ers continued their amiodarone therapy at doses of
400 mg/day for three months and 200 mg/day thereafter.
Non-responders stopped amiodarone and underwent ICD
placement. The best concomitant non-anti-arrhythmic drug
treatment was prescribed to the patients according to their
underlying cardiac disease.
Patients’ follow-up data were obtained by consulting the
flow chart completed during their regular follow-up visit or
by telephone contact with their physician.
“Sudden cardiac death” was defined as death of cardiac
origin occurring unexpectedly within 1 h of the onset of new
symptoms or death that was unwitnessed and unexpected,
unless a specific non-cardiac cause of death was confirmed
(22). In all cases of out-of-hospital death, contact with the
physician and patient’s family was used to classify the
patient’s death.
Statistical analysis. The baseline characteristics of the
patients are expressed as the mean value  SD or propor-
tion (%). The two groups were compared using parametric
or non-parametric tests (Student t, Wilcoxon, Mann-
Whitney U or chi-square test). Survival curves for both
groups were determined according to the Kaplan-Meier
method and were compared using the log-rank test. The
Cox proportional hazards model was used to adjust for
imbalances in baseline prognostic factors and to investigate
potential subgroup effects. For all analyses, p  0.05 was
considered statistically significant. Data were analyzed ac-
cording to the on-treatment principle. Statistical analyses
were performed using S-Plus, version 4.0 (MathSoft Inter-
national, Bagshot, U.K.)
RESULTS
The clinical characteristics of the study group are presented
in Table 1. Both groups are comparable in terms of gender
distribution, LVEF, localization of MI, multiple MIs,
multivessel coronary artery disease, previous coronary artery
bypass graft surgery, New York Heart Association (NYHA)
functional class and concomitant beta-blocker therapy.
However, group 1 patients (amiodarone predicted respond-
ers) were significantly older than group 2 patients (62  9
vs. 57  10 years, p  0.007), and fewer responders to
amiodarone were treated with angiotensin-converting en-
zyme (ACE) inhibitors (63% vs. 88%; p  0.02).
During the first EP study, monomorphic sustained VT
was induced in 79 patients, and VF was induced in 2. The
mean cycle length of induced monomorphic VT was 306 
63 ms. According to the results of the second EP study,
while on amiodarone (mean dose 14  2.9 g orally during
a loading period of 8 to 15 days), 43 patients (51%) were
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
EP  electrophysiological/electrophysiologically
ICD  implantable cardioverter-defibrillator
LV  left ventricle, left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association
SCD  sudden cardiac death
VERP  ventricular effective refractory period
VF  ventricular fibrillation
VT  ventricular tachycardia
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classified as “amiodarone predicted responders” (group 1),
and 41 (49%) as “amiodarone predicted non-responders”
(group 2). The mean cycle length of the sustained ventric-
ular arrhythmia induced during the first EP study was not
significantly different between groups 1 and 2 (304  55 vs.
307  72 ms), nor was the loading dose of amiodarone
(14.2  3.1 vs. 13.8  3 g).
In group 1, during the second EP study with amiodarone
therapy, sustained VT was induced in 30 patients (70%); its
cycle length was significantly prolonged from 304  55 to
426  47 ms (p  0 .0001). The remaining 13 patients had
no sustained ventricular arrhythmia induced. In group 2,
sustained VT was induced in 39 patients, with no significant
change in the basic cycle length (307 72 vs. 316 63 ms),
and in two patients, only VF was inducible. The ventricular
effective refractory period (VERP) at baseline was similar in
both groups and significantly prolonged after amiodarone
loading; there was a non-significant trend toward a greater
prolongation of the VERP in group 1 compared with group
2 (p  0.06).
The clinical presentation of the index arrhythmia differed
between the groups: non-tolerated VT (expressed as syn-
cope or SCD) was significantly more frequent in group 2
patients (p  0.02), but palpitations were significantly more
frequent in group 1 patients (p  0.001).
According to the results of the second EP study, amio-
darone therapy was continued in responders, and all non-
responders received an ICD (6 epicardial systems and 35
non-thoracotomy lead systems). There were no complica-
tions related to the ICD, and all patients were discharged
alive.
Seventeen patients (39%) in group 1 had side effects
during amiodarone therapy, requiring withdrawal of the
drug in six patients: two patients had subsequent ICD
placement, and four were switched to d,l-sotalol therapy.
Four more patients from group 1 underwent subsequent
ICD placement because of the recurrence of VT. One
patient in group 1 and three patients in group 2 underwent
heart transplantation; furthermore, in six group 2 patients
(15%), amiodarone was added again to their drug regimen
to lower the incidence of device therapies.
Mortality. During a mean follow-up period of 63  30
months (range 2 to 123 months) (group 1: 56  30; group
2: 70  28; p  NS), 24 patients died (29%) (Table 2).
Death occurred in 18 patients in group 1 (42%) and in six
patients in group 2 (15%). Ten patients (12%) suffered an
SCD: nine patients in group 1 (21%) and one patient in
group 2 (2%). Seven patients (8%) suffered a non-SCD: five
patients in group 1 and two in group 2. Seven patients (8%)
had a non-cardiac death: four in group 1 and three in group 2.
The actuarial total mortality rate was significantly lower
in group 2 compared with group 1: 0%, 0% and 9% in group
2 versus 12%, 21% and 42% in group 1 at one, three and six
years, respectively (p 0.02) (Fig. 1). Placement of an ICD
Table 1. Clinical Characteristics of the Study Group
Total
(n  84)
Group 1:
Amiodarone-Predicted
Responders
(n  43)
Group 2:
Amiodarone-Predicted
Nonresponders
(n  41) p Value
Male 93% 88% 98% NS
Age (years) 60  10 63  9 57  10 0.007
LVEF (%) 36  11 37  11 35  10 NS
LVEF 35% 46 (55%) 24 (56%) 22 (54%) NS
Anterior MI 18 (21%) 10 (23%) 8 (20%) NS
Inferior MI 46 (55%) 23 (54%) 23 (56%) NS
Multiple MI 18 (21%) 9 (21%) 9 (22%) NS
CABG 22 (26%) 12 (28%) 10 (24%) NS
NYHA functional class II 19 (23%) 11 (26%) 8 (20%) NS
Clinical presentation
Aborted SCD 9 (11%) 3 (7%) 6 (15%) NS
Syncope 24 (29%) 7 (16%) 17 (42%) 0.02
Palpitations 23 (27%) 19 (44%) 4 (10%) 0.001
Electrophysiologic data
TCL* (ms) 306  63 304  55 307  72 NS
TCL† (ms) 360  78§ 426  47§ 316  63 0.0001
VERP* (ms) 238  19 239  16 238  22 NS
VERP† (ms) 271  25§ 276  21§ 265  27¶ 0.06
Delta VERP‡ (ms) 31  22 35  20 26  24 0.11
Drug therapy
Amiodarone (g) 14.0  2.9 14.2  3.1 13.8  2.8 NS
Beta-blockers 18 (21%) 6 (14%) 12 (29%) 0.2
ACE inhibitors 63 (75%) 27 (63%) 36 (88%) 0.02
*Basal state. †After amiodarone administration. ‡Delta VERP VERP† VERP*. §p 0.001 and ¶p 0.001 compared with
the basal state. Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; LVEF  left ventricular ejection
fraction; MI  myocardial infarction; NS  nonsignificant; NYHA  New York Heart Association; SCD  sudden cardiac
death; TCL  tachycardia cycle length; VERP  ventricular effective refractory period.
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was associated with a 78% reduction in total mortality,
compared with amiodarone therapy at six-year follow-up.
The actuarial SCD rate was significantly lower in group 2
compared with group 1: 0%, 0% and 3% in group 2 versus
2%, 8% and 29% in group 1 at one, three and six years,
respectively (p  0.03) (Fig 2).
The only predictive variable for both total mortality and
SCD mortality was a “favorable” response to amiodarone
therapy; syncope or aborted SCD, as the clinical presenta-
tion of the index arrhythmia, was predictive of SCD (p 
0.04). No other tested variable (Table 1) in the Cox
proportional hazards model was predictive of either global
mortality or SCD mortality.
No clinical or EP variable could differentiate inducible
from non-inducible patients in group 1. Three (23%) of 13
non-inducible patients died, all suddenly; there was no
statistically significant difference in the global and SCD
rates (p  0.3 and 0.8, respectively) between patients with
or those without inducible, sustained VT after amiodarone
loading dose in group 1.
Finally, there was a non-significant trend toward a higher
non-SCD rate in group 1 (5 deaths) compared with group
2 (2 deaths) (p  0.07).
DISCUSSION
This study compares the long-term survival rates in patients
who had an MI and a first episode of sustained ventricular
tachyarrhythmia, treated with either amiodarone or an ICD,
according to the results of programmed ventricular stimu-
lation. Our study was not randomized, but reflects the
commonly used clinical practice of placing an ICD when
anti-arrhythmic drugs fail. The present study demonstrates
that total mortality and SCD are significantly higher in
patients treated with amiodarone, even when there is a
favorable response to the drug. These results are in agree-
ment with other published studies comparing anti-
arrhythmic drug treatment and ICD therapy in patients
with sustained ventricular tachyarrhythmias (14,16,17);
however, in these studies, amiodarone was given empiri-
cally, and the effect of amiodarone on VT was not tested in
an EP study (7,23,24).
Table 2. Causes of Death
Total
(n  84)
Group 1
(n  43)
Group 2
(n  41)
Follow-up (months) 63  30 56  30 70  28
Total deaths 24 (29%) 18 (42%) 6 (15%)
SCD 10 (12%) 9 (21%) 1 (2%)
NSCD 7 (8%) 5 (12%) 2 (5%)
Noncardiac deaths 7 (8%) 4 (9%) 3 (7%)
Data are presented as the mean value  SD or number (%) of patients.
NSCD  nonsudden cardiac death; SCD  sudden cardiac death
Figure 1. Global survival was significantly better among patients treated with the implantable cardioverter-defibrillator (ICD), compared with amiodarone.
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Clinical characteristics. Aborted SCD was rare in our
study group: the majority of our patients had sustained VT
but not VF. The clinical presentation of the index arrhyth-
mia was aborted SCD or syncope in 39% of our patients,
which is significantly lower than the rates in other published
studies (14,16,17). Only 23% of our patients were in NYHA
functional class III or IV, and 55% of the patients had an
LVEF 35%. Thus, part of our study group can be
considered as being at low risk, compared with other study
groups, in which there was a higher proportion of patients
with non-tolerated VT as the index arrhythmia
(14,16,17,25,26); this probably explains the lower total
mortality rate in our study group compared with other study
groups.
Group 1 patients had significantly more palpitations and
less syncope than group 2 patients, as the clinical expression
of their index arrhythmia. Hemodynamic tolerance has been
considered as a favorable end point during EP drug testing
and, by definition, characterized our group 1 patients
(7,10,27). These two elements could suggest that group 1
patients had a lower risk of dying suddenly, compared with
group 2 patients. This was not confirmed in our study:
patients treated with amiodarone still have considerably
high sudden and total mortality rates and do less well than
patients treated with an ICD. Electrophysiologic data
during amiodarone therapy (VT cycle length and VERP)
were not predictive of the outcome, indicating that EP
study has no additional value in the management of these
patients. The significant increase in inducible VT cycle
length to hemodynamically tolerated levels in group 1 was
associated with a modest increase (14%) in VERP, com-
pared with previous studies (VERP prolongation of 19% to
23%), in which slowing of the VT cycle length prevented
SCD (8,28–32). Thus, it is possible that the limited effect of
amiodarone on VERP in our patients could not prevent
faster VT, leading subsequently to SCD, but not inducible
during EP study. Furthermore, in group 1, the outcome of
patients with or without inducible sustained VT after a
loading dose of amiodarone did not differ significantly.
Comparison with other studies. The results of our study
are in agreement with recently published data from the
Anti-arrhythmics Vs. Implantable Defibrillators (AVID)
registry (33,34): patients with seemingly low-risk VT have a
mortality similar to that of the higher risk, AVID-eligible
patients with VT. Therefore, patients with post-MI VT
clearly benefit from ICD therapy, compared with amioda-
rone, even if the drug response appears favorable during the
EP study. This strongly suggests that this approach should
be abandoned because of the inability to predict amiodarone
inefficacy using an invasive study. Consequently, according
to a recent subgroup analysis of CIDS data, and on health
and economic grounds, it would be better if amiodarone
Figure 2. Freedom from sudden cardiac death. The sudden cardiac death rate was significantly lower in patients treated with the implantable
cardioverter-defibrillator (ICD), compared with amiodarone.
1817JACC Vol. 39, No. 11, 2002 Schla¨pfer et al.
June 5, 2002:1813–9 Amiodarone vs. ICD: Long-Term Survival
were prescribed using simple clinical predictors such as age,
functional status and LVEF that help target patients who
might not have an additional benefit from expensive ICD
therapy (19).
The better outcome in terms of global mortality in our
ICD-treated patients, compared with group 1 patients, is
essentially related to a far lower SCD rate, as expected with
ICD therapy (35,36). There was also a trend toward a lower
non-SCD rate in our ICD group, suggesting that several
selection biases might have been introduced; however, other
published studies have shown an unexpected significant
reduction in the non-SCD rate in patients treated with an
ICD when compared with amiodarone therapy (16,30,37).
Both of our groups had a rate of SCD similar to that in
earlier studies, but they differ in a lower overall death rate,
owing to a lower non-SCD rate (4,36,37). This could be
due to several biases (36,37) and might be explained by a
different observed study group, owing to the inclusion of
lower-risk patients, use of specific inclusion criteria, intro-
duction of new drug treatments (e.g., beta-blockers, ACE
inhibitors) or the fact that our study was observational in
design and did not follow randomized patients.
Although responders and non-responders to amiodarone
were similar in terms of multiple clinical variables (Table 1),
group 1 patients were significantly older than group 2
patients. This unexpected finding was not reported in other
studies testing amiodarone efficacy and is probably related to
our specific inclusion criteria used for the definition of group
1 patients. Younger age could have resulted in the better
outcome in ICD patients (group 2). However, the signifi-
cant difference in terms of both total mortality and SCD
still persists after adjustment for age in the multivariate
analysis. Finally, an imbalance in ACE-inhibitor therapy
could have favored the outcome in ICD-treated patients
(38).
Study limitations. Our study is a single-center, prospec-
tive, observational study that included a limited number of
patients during a nine-year follow-up period. This could
have introduced several biases because there was a signifi-
cant evolution during the recruitment period in the global
management of patients with ischemic heart disease (30,31).
However, long recruitment periods were also observed in
the Cardiac Arrest Study Hamburg (CASH) and AVID
trials (7,10). Our study group is quite homogeneous, rep-
resenting 91% of post-MI patients with sustained VT
referred for EP evaluation, and our group 2 patients
represent 94% of all patients implanted with an ICD for
sustained VT after an MI; thus, only a few patients escape
our protocol during this long inclusion period. As stated
earlier, an important limitation of our non-randomized
study is the significant imbalance in ACE-inhibitor therapy,
as well as the trend toward an imbalance in beta-blocker use
in the amiodarone group, which might explain a higher
mortality rate.
The role of programmed ventricular stimulation in as-
sessing the protective effect of amiodarone is still contro-
versial. The criteria we used to evaluate amiodarone efficacy
during the second EP study were non-inducibility and good
hemodynamic tolerance of induced VT; both end points
have been considered as good prognostic indexes by several
authors (12,39), but they turned out to have no prognostic
value in our study. Furthermore, VERP was also not
predictive of the outcome in either group. Therefore, the
data suggest that these end points must be abandoned or
that EP testing is not valid during amiodarone therapy. The
loading dose of amiodarone was prescribed during a period
varying between 8 and 15 days, which could induce a bias in
the study, and amiodarone plasma levels were not measured.
However, the loading dose of amiodarone in our study is in
accordance with the dose used in other studies
(17,24,39,40).
Conclusions. Our study demonstrates that patients with
depressed LV function, having suffered sustained VT after
MI, have a better long-term outcome when treated with an
ICD, compared with amiodarone therapy, even if stratified
according to the results of the EP study. These patients
should benefit from early ICD placement; any previous
amiodarone treatment seems to have no additional value.
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